Ocugen updates Q3 2026 results; grants rights for OCU400; sets PATH for phase 3 data
Ocugen reported $84.6 million in cash and provided an update on its OCU400 and OCU410 candidate programs; markets reacted positively to the company's international licensing agreement for OCU400.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed